William Blair Brokers Decrease Earnings Estimates for SLP

Simulations Plus, Inc. (NASDAQ:SLP) – Analysts at William Blair lowered their Q3 2026 earnings estimates for shares of Simulations Plus in a note issued to investors on Monday, January 27th. William Blair analyst M. Smock now anticipates that the technology company will post earnings per share of $0.43 for the quarter, down from their previous forecast of $0.44. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Simulations Plus’ current full-year earnings is $1.09 per share.

Several other equities research analysts have also issued reports on the stock. Stephens assumed coverage on shares of Simulations Plus in a research note on Friday, November 15th. They issued an “overweight” rating and a $39.00 price target on the stock. KeyCorp lifted their target price on Simulations Plus from $35.00 to $37.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. BTIG Research reduced their price target on Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. Finally, StockNews.com lowered Simulations Plus from a “hold” rating to a “sell” rating in a research report on Monday, November 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $49.40.

Simulations Plus Stock Up 1.4 %

Shares of SLP stock opened at $34.27 on Thursday. Simulations Plus has a 12 month low of $24.00 and a 12 month high of $51.22. The company’s fifty day simple moving average is $30.31 and its 200-day simple moving average is $32.70. The firm has a market cap of $688.48 million, a PE ratio of 85.68 and a beta of 0.80.

Hedge Funds Weigh In On Simulations Plus

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Conestoga Capital Advisors LLC increased its stake in shares of Simulations Plus by 15.0% in the fourth quarter. Conestoga Capital Advisors LLC now owns 2,226,262 shares of the technology company’s stock valued at $62,090,000 after buying an additional 290,414 shares during the period. State Street Corp lifted its position in shares of Simulations Plus by 4.7% in the 3rd quarter. State Street Corp now owns 640,303 shares of the technology company’s stock worth $20,503,000 after purchasing an additional 28,953 shares during the period. Geode Capital Management LLC boosted its position in Simulations Plus by 4.4% during the third quarter. Geode Capital Management LLC now owns 448,618 shares of the technology company’s stock valued at $14,367,000 after acquiring an additional 18,924 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Simulations Plus by 10.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 414,005 shares of the technology company’s stock valued at $20,128,000 after purchasing an additional 37,992 shares in the last quarter. Finally, Tributary Capital Management LLC boosted its holdings in shares of Simulations Plus by 21.7% during the 4th quarter. Tributary Capital Management LLC now owns 396,093 shares of the technology company’s stock worth $11,047,000 after buying an additional 70,526 shares in the last quarter. Institutional investors own 78.08% of the company’s stock.

Insider Activity

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $31.76, for a total transaction of $635,200.00. Following the completion of the transaction, the director now owns 3,442,584 shares of the company’s stock, valued at approximately $109,336,467.84. The trade was a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 19.40% of the company’s stock.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.